Please note that following on from information provided to NICE by the company in November 2016, the appraisal of Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 986 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in November 2016, the appraisal of Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 01 December 2016 | Suspended. Please be advised that the Department of Health has asked us to carry out a Single Technology Appraisal of nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma. However, the company have advised that they will not be seeking regulatory approval from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes |
| 22 July 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual